Abstract:p21(WAF1/CIP1) plays a major role in the induction of G(1) arrest following DNA damage. Although p21(WAF1/CIP1) expression is regulated by the tumor suppressor p53, induction of p21(WAF1/CIP1) expression through p53-independent pathways has been described in numerous cell types. In this report, we describe the mechanism by which the retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) induces p21(WAF1/CIP1) in breast carcinoma cells possessing either a wild-type (MCP-7 cells) or mutated (MDA-MB-468 cells) p53. Exposure of MDA-MB-468 cells to this retinoid results in an approximately 10-fold increase in p21(WAF1/CIP1) mRNA levels, whereas less than a 2-fold increase in p21(WAF1/CIP1) gene transcription was observed as indicated by transient transfection experiments utilizing a p21(WAF1/CIP1) promoter firefly luciferase reporter gene construct and nuclear run-off studies. We found similar results in the MCF-7 cells (Z-M. Shao et al., Oncogene, 11: 493-504, 1995), We have now found that while enhancing p21(WAF1/CIP1) gene transcription minimally, this retinoid increases p21(WAF1/CIP1) mRNA stability by 3-fold in both cell types. We also demonstrate that similar to 1.5 kb of the 3' untranslated region causes enhanced instability of p21(WAF1/CIP1) mRNA. The retinoid-dependent increase in p21(WAF1/CIP1) mRNA stability is accompanied by an increase in p21(WAF1/CIP1) protein expression, as indicated by Western blot experiments utilizing anti-p21(WAF1/CIP1) monoclonal antibody. This increase in p21(WAF1/CIP1) is subsequently followed by the onset of programmed cell death in both cell types. Thus, CD437 is a novel retinoid which enhances p21(WAF1/CIP1) mRNA levels through stabilization of the message regardless of the p53 status of the cell.

A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen

Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1

Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1

Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design

Highly potent p21WAF1‐derived peptide inhibitors of CDK‐mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin A

A P21(Waf1/Cip1) Carboxyl-Terminal Peptide Exhibited Cyclin-Dependent Kinase-Inhibitory Activity And Cytotoxicity When Introduced Into Human Cells

CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication

Inhibition of Cyclin-Dependent Kinases by P21.

A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases

P21 Disrupts the Interaction Between Cdk2 and the E2F-p130 Complex.

Posttranscriptional Regulation Of P21(Waf1/Cip1) Expression In Human Breast Carcinoma Cells

p21: A Two-Faced Genome Guardian

A Novel Cycline/cyclina-Cdk Inhibitor Targets P27(kip1) Degradation, Cell Cycle Progression and Cell Survival: Implications in Cancer Therapy.

Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair

p21 in cancer: intricate networks and multiple activities

Pim-2 phosphorylation of p21Cip1/WAF1 enhances its stability and inhibits cell proliferation in HCT116 cells

Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F

Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes

Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl

Killin is a P53-Regulated Nuclear Inhibitor of DNA Synthesis